Kodiak Sciences Q2 net loss $54.3M, cash $104.2M; pipeline milestones on track

Kodiak Sciences Inc.

2025-Q2 EPS reported -$2.12

Net loss of $54.3M ($1.03/share) vs $45.1M loss a year ago; R&D expenses rose to $42.8M.
Cash and equivalents $104.2M; expected to fund operations into 2026.
Tarcocimab Phase 3 GLOW2 topline data expected Q1 2026; DAYBREAK (wet AMD) topline in Q3 2026.
KSI-101 Phase 1b MESI data: half of patients ≥15 letter gain at Week 12; Phase 3 enrolling.
Investor R&D Day on July 16, 2025 presented 12-week KSI-101 data and commercial strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.